37 results about "Tizanidine" patented technology

A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms of acute or chronic cardiac insult or impaired cardiac performance. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and / or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with cardiac insult or impaired cardiac performance and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist (e.g., clonidine, p-aminoclonidine, guanabenz, lidamidine, tizanidine, moxonidine, methyldopa, xylazine, guanfacine, detomidine, medetomidine, and dexmedetomidine).

A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms and otherwise treat heart failure (HF) and pathologies associated with HF. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and / or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with HF (or pathologies associated with HF) and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist, e.g., clonidine, p-aminoclonidine, guanabenz, lidamidine, tizanidine, moxonidine, methyldopa, xylazine, guanfacine, detomidine, medetomidine, and dexmedetomidine.

A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms and otherwise treat heart failure (HF) and pathologies associated with HF. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and / or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with HF (or pathologies associated with HF) and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist, e.g., clonidine, p-aminoclonidine, guanabenz, lidamidine, tizanidine, moxonidine, methyldopa, xylazine, guanfacine, detomidine, medetomidine, and dexmedetomidine.

Pharmaceutical compositions comprising at least one alpha2-adrenergic agonist or baclofen and at least one alpha1-adrenergic agonist are disclosed. Pharmaceutical compositions comprising tizanidine and modafinil are disclosed. Methods for reducing somnolence, sleepiness, lethargy, dizziness, drowsiness, somnolence, tiredness, lightheadedness, increased weakness, confusion, unsteadiness, clumsiness, or a combination of the symptoms thereof in a human patient; treating pain; and attenuating muscle spasticity, using pharmaceutical compositions comprising at least one alpha2-adrenergic agonist or baclofen and at least one alpha1-adrenergic agonist are disclosed.

A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms of acute or chronic cardiac insult or impaired cardiac performance. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and / or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with cardiac insult or impaired cardiac performance and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist (e.g., clonidine, p-aminoclonidine, guanabenz, lidamidine, tizanidine, moxonidine, methyldopa, xylazine, guanfacine, detomidine, medetomidine, and dexmedetomidine).

Disclosed is an extended release pharmaceutical formulation containing at least an alpha-2 adrenergic agonist, such as tizanidine, for the treatment and prevention of spasticity in a subject, e.g., painful inflammatory conditions associated with skeletal muscle spasms.

Disclosed is an extended release pharmaceutical formulation comprising a muscle relaxant drug, such as tizanidine, in combination with a cyclooxygenase-2 inhibitor, such as valdecoxib. The formulations are useful in the treatment and management of painful inflammatory conditions associated with, for example, skeletal muscle spasms.

An application of tizanidine or its derivative in preparing the medicines for treating insomnia, elongating SWS sleeping and preventing senile dementia is disclosed.

The invention is directed to methods of treating spasticity in patient having a neurological disease comprising administering to a patient in need of such treatment a tizanidine formulation providing a tizanidine blood concentration of at least about 900 pg / ml for about five hours, wherein the formulation is administered prior to bedtime.

The present invention relates to a novel controlled release formulations of tizanidine. The invention also provides methods of using novel controlled release formulations of tizanidine to treat a patient.

The present invention relates to a novel controlled release formulations of tizanidine. The invention also provides methods of using novel controlled release formulations of tizanidine to treat a patient.

A method of treating the symptoms of spasticity comprises implanting a reservoir-based drug delivery composition into a subject to systemically deliver a therapeutically effective amount of tizanidine to the subject for a long period of time (e.g., one month or one year). The drug delivery composition may include a rate-controlling excipient (e.g., an elastomeric polymer) defining a reservoir containing at least one discrete solid dosage form (e.g., one or more pellets), which includes tizanidine free base and optionally, a sorption enhancer.

The subject invention describes a method of use of Ropinirole™ to alleviate and control menopausal symptoms in women, and in particular, hot flashes. The invention describes the use of Ropinirole as a dopamine agonist with affinity for the dopamine D2, D3, or D4 receptors. Ropinirole may also be used to treat menopausal symptoms in conjunction with Tizanidine™ to further reduce the effects menopausal symptoms by providing a sedative and muscle relaxant effect which aids in sleep. The combination of Ropinirole and Tizanidine provides a useful new compound for treatment of menopausal symptoms that are most disruptive to the functioning in activities of daily living.

An article and method for increasing the extent of tizanidine absorption in a patient receiving tizanidine therapy. Tizanidine may be administered in the form of an immediate release tablet composition at or around the time food is consumed. The composition may be packaged in a container for distribution.

A slowly-released medicine of tizanidine in the form of dispersing solid is prepared from tizanidine and slow-releasing skeleton.

A method of treating the symptoms of spasticity comprises implanting a reservoir-based drug delivery composition into a subject to systemically deliver a therapeutically effective amount of tizanidine to the subject for a long period of time (e.g., one month or one year). The drug delivery composition may include a rate-controlling excipient (e.g., an elastomeric polymer) defining a reservoir containing at least one discrete solid dosage form (e.g., one or more pellets), which includes tizanidine free base and optionally, a sorption enhancer.

An article and method for reducing somnolence in a patient receiving tizanidine therapy. Tizanidine may be administered in the form of an immediate release multiparticulate composition at or around the time food is consumed. The composition may be packaged in a container for distribution.

An article and method for reducing somnolence in a patient receiving tizanidine therapy. Tizanidine may be administered in the form of an immediate release multiparticulate composition at or around the time food is consumed. The composition may be packaged in a container for distribution.

A tizanidine liquid preparation and use of the tizanidine liquid preparation in the preparation of a medicament for treating muscle spasm, wherein the tizanidine liquid preparation comprises an active ingredient, a stabilizing agent and other pharmaceutical excipients, wherein the active ingredient is one or more of tizanidine or a pharmaceutically acceptable salt, solvate and hydrate thereof.

The invention relates to a tizanidine crystal form, and belongs to the technical field of pharmaceutical chemicals. The X-ray diffraction pattern of the tizanidine crystal form has characteristic peaks at 7.0 + / -0.2 degrees, 9.8 + / -0.2 degrees, 14.1 + / -0.2 degrees, 15.7 + / -0.2 degrees, 17.9 + / -0.2 degrees, 20.0 + / -0.2 degrees, 21.4 + / -0.2 degrees, 23.6 + / -0.2 degrees, 24.7 + / -0.2 degrees, 25.4 + / -0.2 degrees, 26.5 + / -0.2 degrees, 27.4 + / -0.2 degrees, 28.6 + / -0.2 degrees, 29.3 + / -0.2 degrees and 30.0 + / -0.2 degrees; the invention also provides a related preparation method. The tizanidine crystal form disclosed by the invention is relatively good in stability and relatively high in water solubility, the bioavailability can be increased and the drug effect can be improved by utilizing the tizanidine crystal form to prepare drugs, and the tizanidine crystal form is simple in production operation and easy to commercialize.

The invention relates to a nizatidine and it's derivate, wherein it contains the general-release paret whose active compotents are nizatidine and its derivate, and the slow-release part, while the mol ratio between nizatidine and derivate are 5-95:5-95. The invention also provides a relative preparation. The test has proves that its effect is higher than slow-release agent, and its rate of side effect is lower than general-release agent.

The invention relates to a tizanidine and meloxicil rehabilitation compound which is good in stability, remarkable in analgesic effect and better in human body bioavailability. The invention also relates to a preparation method and application of the tizanidine and meloxicil rehabilitation composition.

The present invention relates to a tizanidine and meloxicam compound. The compound features good stability, remarkable analgesic effect, and better bioavailability in humans. The present invention further relates to a preparation method for and use of the tizanidine and meloxicam compound.

The present invention relates to method of increasing the bioavailability / bio-efficacy of tizanidine by co-administering with resveratrol and bioenhancer. The formulation comprising tizanidine, resvetarol and bioenhancer are also provided which can be used for treatment of muscle spasticity.

The invention provides a tizanidine nitrate crystal form A, and a preparation method and applications thereof. The provided tizanidine nitrate crystal form A uses a Cu-K[alpha] radiation source to perform X-ray powder diffraction, and a 2[theta] diffraction angle has characteristic absorption peaks at 11.4 + / - 0.2, 20.8 + / - 0.2, 21.8 + / - 0.2, 23.2 + / - 0.2 and 26.7 + / - 0.2 degrees; the crystal formA is high in chemical purity, stable in property and low in hygroscopicity, and an effective solution can be provided for the improvement of the availability and security of drugs; and in addition, the crystal form A is simple in preparation technology, short in reaction time and high in product yield, and has no special requirements on equipment, so that the crystal form A is suitable for industrial production.

An application of tizanidine or its derivative in preparing the medicines for treating insomnia, elongating SWS sleeping and preventing senile dementia is disclosed.

The invention discloses an anti-tumor pharmaceutical composition. The active ingredients in the pharmaceutical composition are tizanidine and docetaxel. The two effective components of the pharmaceutical composition generate a synergistic effect, so that the drug sensitivity can be enhanced, and in addition, the docetaxel dosage and the toxic and side effects can be reduced.

The invention discloses a tizanidine liquid preparation. The liquid preparation comprises an active component, EDTA (Ethylene Diamine Tetraacetic Acid) disodium and other medicine excipients, the active ingredient is one or more of tizanidine or pharmaceutically acceptable salt, solvate and hydrate of tizanidine; the invention also discloses application of the tizanidine liquid preparation in preparation of a medicine for treating muscle spasm. The liquid preparation has good chemical and physical stability, the bioavailability of the liquid preparation is equivalent to that of an existing tizanidine solid preparation on the market before and after meals, the influence of food on the medicine action speed is small, the medicine action speed under the postprandial condition is higher than that of the solid preparation, meanwhile, the occurrence rate of adverse reactions is reduced, and the effect of the liquid preparation is improved. The dosage titration device has the advantage of more convenience in dosage titration adjustment, is also easy to improve the medicine taking compliance of infants, old people, patients with dysphagia, some mental disease patients and bedridden patients of which the body positions are difficult to change, and meets clinical requirements.

The disclosure is directed to pharmaceutical compositions comprising of Tizanidine or a pharmaceutically acceptable salt thereof which controllably modulate the onset of at least one secondary effect associated with Tizanidine administration. In embodiments, the pharmaceutical compositions comprise at least three components with different release characteristics: immediate release component; a first time, pulsatile release component; and a second population of time, pulsatile release component. The release characteristics of the pharmaceutical composition are such that the bedtime blood plasma concentrations control spasticity and allow the patient to have quality sleep, and the daytime blood plasma concentrations controls spasticity without unwanted secondary such as somnolence or sedation.